Previous close | 3.6500 |
Open | 3.8400 |
Bid | 3.6600 x 200 |
Ask | 3.7300 x 200 |
Day's range | 3.6350 - 3.8850 |
52-week range | 1.4500 - 4.9100 |
Volume | |
Avg. volume | 603,177 |
Market cap | 261.063M |
Beta (5Y monthly) | 2.05 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.9400 |
Earnings date | 01 Aug 2024 - 05 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 6.57 |
REDWOOD CITY, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has successfully synthesized an oligonucleotide via an enzymatic route to support RNA-based therapeutics manufacturing. Data highlighting this historic manufacturing milestone are being presented today in a Spotlight Presentation at the TIDES USA annual meeting taking place in Boston, MA, and virtually May 14 – 17, 2024. “The data presented today by Codexi
Codexis ( NASDAQ:CDXS ) First Quarter 2024 Results Key Financial Results Revenue: US$17.1m (up 32% from 1Q 2023). Net...
Codexis, Inc. (NASDAQ:CDXS) Q1 2024 Earnings Call Transcript May 2, 2024 Codexis, Inc. beats earnings expectations. Reported EPS is $-0.1647, expectations were $-0.17. Codexis, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to the Codexis’ First Quarter 2024 […]